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Letters 
NO DETECT ION OF MACROPHAGE ERYTHRO-  
POIET IN  PRODUCTION IN BONE MARROW 
FROM RHEUMATOID ARTHRIT IS  PAT IENTS 
WITH AND WITHOUT ANAEMIA  AND CON- 
TROLS 
To the Editor 
Anaemia is a common extraarticular manifestation f rheuma- 
toid arthritis (RA). Apart from deficiencies of iron, vitamin 
B12 and folic acid and adverse antirheumatic drug reactions, 
the anaemia of chronic disease (ACD) is the most frequent 
cause of anaemia in RA (1). Much research as been carried 
out to examine its pathophysiology, such as altered iron me- 
tabolism (2,3) and cytokines - like interleukin 1 and tumour 
necrosis factor, which may suppress erythropoiesis (4). Anoth- 
er mechanism underlying ACD in RA might be an insufficient 
erythropoietin (Epo) responsiveness to the anaemia (1,5) or 
decreased erythroblast-Epo sensitivity based on findings that 
Epo-induced erythroid growth is reduced in RA complicated 
by ACD (6). Rich reported that macrophages in bone marrow 
are able to produce and release Epo depending on local pH 
and oxygen tension (7) and exhibit Epo gene expression (8). 
These observations prompted us to investigate whether Epo 
production isdetectable inbone marrow derived from RA pa- 
tients and controls and whether Epo production by marrow 
macrophages and its metabolism is altered in ACD. 
Serum and bone marrow were obtained from 5 nonanaemic 
RA patients, 5 RA patients with ACD (based on normal to 
increased bone marrow iron stores and the exclusion of other 
causes of anaemia) and 4 controls (bone marrow transplant do- 
nors), after they gave written informed consent. Mean age of 
Table I : Parameters of elythropoiesis, RA activity, iron status and mar- 
row Epb production RA patients with ACD and without anaemia 
ACD Nonanemics Controls 
(n=5) (n=5) (n=4) 
Hb 10.8"* 12.7 13.0 
(g/l) (9.2-11.1) (11.9-14.0) (12.4-13.2) 
Ht 0.33"* 0.37 0.40 
(1/1) (0.28-0.35) (0.36-0.41) (0.37-0.40) 
ESR 87** 36* 14 
(mm/h) (52-92) (21-65) (12-16) 
CRP 31"* 22* 3 
(mg/1) (11-74) (2-54) (2-4) 
Ferritin 121"* 53* 22 
(ug/1) (89-432) (10-326) (10-34) 
EPO <0.1 <0.1 <0.1 
(mU/ml) . . . . . .  
EPO + + 410 470 430 
(mU/ml) (380-470) (360-475)  (420-475) 
Data are expressed asmedian (range); *p<0.10 ; ** p<0.05 compared 
to controls ; + + Epo concentration after addition of 1 U/ml Epo to 
the medium. 
the RA patients was 59( -+ 6) years and of the controls 32( - 4) 
years. None of the RA subjects were treated with steroids or 
cytostatic drugs. After Ficoll separation, one million mononu- 
clear cells were added to a medium containing the usual sub- 
stances for BFUe colony assessment (9), up to volume of 1 ml. 
It was then incubated for 48 hours at 37 degrees centigrade 
and 100% humidity in 5% CO 2. This procedure was repeated 
with the addition of 1 U/ml of Epo (Boehringer Vienna, Aus- 
tria). The cell suspension was centrifuged and the supernatant 
was tested for Epo, using an ELISA Epo assay as recently de- 
veloped (Boehringer Mannheim, W-Germany; lowest detec- 
tion level 0.1 mU/ml, reference values in serum 0.4-8.9 
mU/ml). The results are shown in Table I. No Epo could be 
detected in any of the marrow cultures of the three groups. Af- 
ter the addition of Epo to the cultures less than 50% was re- 
covered after 48 hours of culturing. 
These observations may indicate that Epo production and/or 
release by marrow macrophages in culture is not detectable in
the three groups studied here. The second experiment shows 
that recovery of Epo added to the cultures is less than 50%, 
suggesting that Epo is metabolized, adhered to or incorporated 
into the marrow cells, which were washed away in these ex- 
periments. The Epo initially produced in the marrow cultures 
in the first experiment might have been below the detection 
limit or metabolized before measurement. Apparently net 
macrophage Epo production or release after 48 hours of cul- 
turing is undetectable in either group and Epo metabolism is 
similar in the three groups. Consequently, these preliminary 
data do not support he concept of altered marrow Epo pro- 
duction or metabolism by macrophages or other cells present 
in bone marrow as a cause of ACD in RA. 
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HERPES S IMPLEX V IRUS ANT IGENS IN SERA 
OF  PAT IENTS WITH BEHCET 'S  D ISEASE 
To the Editor: 
In a recent study, it was reported that titres of IgG antibodies 
to herpes implex virus type 1 (HSV-1) were significantly high- 
er in the sera of patients with Behcet's disease (BD). Levels 
of IgG antibodies were significantly higher in patients with ac- 
tive disease than in patients with inactive disease. These results 
suggested some evidence for involvement of HSV-1 in the im- 
munopathogenesis of BD (1). In the present study we inves- 
tigate HSV antigens in the sera of patients with BD. 
Twenty patients (19 male, one female) with a mean age of 
39 +- 3 (range 29-58) were studied. Disease duration was 6.8 -+ 
1.9 (range 2-25). All patients fulfilled the diagnosis criteria 
proposed by the International Study Group for Behcet's dis- 
ease (2). Clinical manifestations were as follows : buccal aph- 
thosis (n = 20) genital aphthosis (n = 17), necrotic pseudo- 
folliculitis (n = 15), dermohypodermal lesions (n = 5) positive 
pathergic test (n = 13) venous thrombosis (n = 8), arthritis 
(n = 7) central nervous ystem (= 3) arterial aneurysm (n = 
2). The disease was active in 12 patients and inactive in 8. 
Antigens present in sera of BD patients at different stages 
were investigated using an ELISA technique. Monoclonal an- 
tibodies against HSV-1 and 2 were fixed on wells of polystyrene 
plates. 100 microliters of sera were incubated pure and at 1:10 
for one hour at 37~ After washing, 100 microliters of anti 
HSV monoclonal ntibody was added (1:50 for one hour). Af- 
ter washing, phosphatase alcaline conjugate was added for 
1 hour (100 microliters). Finally, 100 microliters of phos- 
phatase alcaline substrate were used for 20 rain. 
Positive controls used were HSV-1 and 2 strains purified in ul- 
tracentrifugation gradient sucrose and ultrasonicated. Nega- 
tive controls were PBS. Positive controls had a high optical 
density at 405 nm (> 0.6). Negative controls were always < 0.15. 
On the 20 patients tested, none had positive results by this as- 
say. 
Reactivation of the BD does not seem to be associated with 
liberation of HSV particles in the sera but with rise of anti- 
bodies against HSV as previously described. 
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